Antje Sucker

Essen, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 122 publications

Melanoma of unknown primary shows an oncogenic pattern and clinical course of sun-exposed melanoma.

Melanoma of unknown primary shows an oncogenic pattern and clinical course of sun-exposed melanoma.

Journal: The British journal of dermatology

Published: August 06, 2025

Exceptional therapeutic benefit of imatinib in cKIT-mutated mucosal melanoma followed by a KIT mutation loss.

Exceptional therapeutic benefit of imatinib in cKIT-mutated mucosal melanoma followed by a KIT mutation loss.

Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Published: March 10, 2025

pTERT mutational status is associated with survival in stage IV melanoma patients receiving first-line immune therapy.

pTERT mutational status is associated with survival in stage IV melanoma patients receiving first-line immune therapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 19, 2024

Constitutive expression of the transcriptional co-activator IκBζ promotes melanoma growth and immunotherapy resistance.

Constitutive expression of the transcriptional co-activator IκBζ promotes melanoma growth and immunotherapy resistance.

Journal: Nature communications

Published: October 13, 2024

Early versus late response to PD-1-based immunotherapy in metastatic melanoma.

Early versus late response to PD-1-based immunotherapy in metastatic melanoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 05, 2024

Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomas.

Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomas.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 10, 2024

Single-cell RNA and T-cell receptor sequencing unveil mycosis fungoides heterogeneity and a possible gene signature.

Single-cell RNA and T-cell receptor sequencing unveil mycosis fungoides heterogeneity and a possible gene signature.

Journal: Frontiers in oncology

Published: March 28, 2024

Clinical and genetic characteristics of BAP1-mutated non-uveal and uveal melanoma.

Clinical and genetic characteristics of BAP1-mutated non-uveal and uveal melanoma.

Journal: Frontiers in immunology

Published: February 06, 2024

Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.

Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.

Journal: Nature cancer

Published: August 14, 2023

Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM.

Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM.

Journal: EBioMedicine

Published: March 31, 2023

Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma.

Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma.

Journal: Journal for immunotherapy of cancer

Published: March 14, 2023

HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance.

HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 12, 2023

Showing 1-12 of 122

Last Updated: 09/26/2026